CD8+ S100B+ T cells

Overview

CD8+ S100B+ T cells represent a specialized subset of cytotoxic T lymphocytes characterized by the expression of the S100B protein, which is implicated in various immune responses and tumor microenvironments. These T cells play a crucial role in the adaptive immune system, particularly in recognizing and eliminating cancer cells. The presence of S100B in CD8+ T cells may influence their activation, proliferation, and cytotoxic functions, making them a significant focus in cancer immunotherapy research. Understanding the mechanisms governing CD8+ S100B+ T cell activity can provide insights into enhancing anti-tumor immunity and developing novel therapeutic strategies.

Focus of Latest Publications

Recent studies have highlighted the importance of CD8+ S100B+ T cells in various cancer contexts, particularly in relation to tumor immunogenicity and the tumor microenvironment. For instance, a study published in Oncoimmunology (PMID: 42057381) demonstrated that BET inhibition using JQ1 enhanced the proliferation of tumor-infiltrating lymphocytes (TILs), leading to an enriched population of CD8+ T cells, suggesting a pivotal role for these cells in anti-tumor responses. Another study in Epigenetics (PMID: 42118848) reported that a high-risk group exhibited an immunosuppressive microenvironment with reduced CD8+ T cells, indicating the prognostic impact of cytotoxic T-cell infiltration on tumor progression.

Moreover, research in Blood Advances (PMID: 41941698) emphasized the significance of CD8+ T cell subsets in driving immune responses post-vaccination, while a study in Cancer Cell (PMID: 42242231) associated reduced intratumoral regulatory T cells with enhanced CD8+ T cell effector function, underscoring the dynamic interplay between different immune cell types in the tumor microenvironment. Combination therapy with anti-PD-1 antibodies enhanced CD8+ T-cell recruitment and function in hepatocellular carcinoma models (PMID: 42111772), further illustrating the relevance of cytotoxic T cells in immunotherapy and resistance reversal.

Additionally, the role of CD8+ S100B+ T cells in modulating immune responses was explored in the context of various therapeutic strategies, including the use of lipid nanoparticles (PMID: 42057038) and adoptive T cell transfer (PMID: 41998001). These studies collectively suggest that enhancing the function and infiltration of CD8+ S100B+ T cells could be a promising approach for improving cancer immunotherapy outcomes.